VIR-7831 Supply Agreement for Pandemic Purposes

Descriptions

The evolution of the UK's pandemic response has highlighted the critical importance and economic value of a multi-layered and comprehensive approach to COVID-19. The need for antibodies and other therapeutics has always been under consideration, the mutation of the virus and the risk this poses on antibody and vaccine efficacy has only recently been properly identified and still requires further academic studies. These unforeseen circumstances mean there is now a critical, urgent need to procure and deploy a new class of mAbs, that can neutralise any COVID-19 variant. These neutralising mAbs provide protection to a cohort of the population who, for medical reasons, cannot mount an appropriate immune response to vaccination or, for whatever reason, do not get vaccinated and are also at higher risk of hospitalisation or death. This agreement is for the procurement of 100,008 units of Sotrovimab (VIR-7831).